Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Dicerna Pharmaceuticals	Axsome Therapeutics	Revance Therapeutics	NGM Biopharmaceuticals	Morphic
Symbol	NASDAQ:DRNA	NASDAQ:AXSM	NASDAQ:RVNC	NASDAQ:NGM	NASDAQ:MORF
Price Information
Current Price	$25.11	$60.03	$27.89	$27.98	$48.00
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	2.0	1.6	1.7	1.7	1.5
Analysis Score	4.5	3.4	3.5	3.6	3.5
Community Score	3.0	2.7	2.6	3.4	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	1.7	1.7
Earnings & Valuation Score	0.6	0.0	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$42.29	$133.83	$38.50	$39.11	$85.00
% Upside from Price Target	68.40% upside	122.94% upside	38.04% upside	39.78% upside	77.08% upside
Trade Information
Market Cap	$1.93 billion	$2.26 billion	$1.99 billion	$2.15 billion	$1.74 billion
Beta	1.33	2.59	1.42	1.97	1.01
Average Volume	795,762	342,411	430,277	256,673	342,508
Sales & Book Value
Annual Revenue	$23.90 million	N/A	$410,000.00	$103.54 million	$16.98 million
Price / Sales	80.79	N/A	4,855.79	20.81	102.37
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.22 per share	$5.18 per share	$5.00 per share	$4.96 per share	$4.62 per share
Price / Book	11.31	N/A	5.58	5.64	10.39
Profitability
Net Income	$-120,460,000.00	$-68,350,000.00	$-159,430,000.00	$-42,790,000.00	$-43,330,000.00
EPS	($1.76)	($2.01)	($3.67)	($0.85)	($2.69)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-88.81%	N/A	-5,818.87%	-91.64%	N/A
Return on Equity (ROE)	-71.72%	-62.33%	-85.72%	-29.47%	-36.62%
Return on Assets (ROA)	-16.60%	-47.87%	-44.85%	-25.58%	-20.69%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.36%	0.48%	N/A	N/A
Current Ratio	2.62%	9.99%	7.07%	8.01%	6.14%
Quick Ratio	2.62%	9.99%	7.01%	8.01%	6.14%
Ownership Information
Institutional Ownership Percentage	80.64%	63.64%	74.35%	49.56%	61.49%
Insider Ownership Percentage	11.30%	26.00%	4.80%	50.40%	39.50%
Miscellaneous
Employees	302	60	470	210	94
Shares Outstanding	76.90 million	37.57 million	71.38 million	77.02 million	36.21 million
Next Earnings Date	8/5/2021 (Estimated)	8/9/2021 (Estimated)	8/5/2021 (Estimated)	8/11/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	Morphic (NASDAQ:MORF) Price Target Cut to $102.00 by Analysts at BMO Capital Markets americanbankingnews.com - May 10 at 9:06 AM
	Newsflash: Morphic Holding, Inc. (NASDAQ:MORF) Analysts Have Been Trimming Their Revenue Forecasts finance.yahoo.com - May 5 at 8:10 AM
	RBC Capital Stick to Their Buy Rating for Morphic Holding Inc investing.com - May 4 at 10:09 AM
	Morphic Holding, Inc. (NASDAQ:MORF) Director Sells $523,113.18 in Stock americanbankingnews.com - May 3 at 5:02 PM
	BMO Capital Markets Trims Morphic (NASDAQ:MORF) Target Price to $102.00 americanbankingnews.com - May 3 at 8:04 AM
	Morphic (NASDAQ:MORF) Issues Earnings Results, Misses Estimates By $0.08 EPS americanbankingnews.com - April 30 at 3:42 PM
	Insider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 10,704 Shares of Stock americanbankingnews.com - April 29 at 4:42 PM
	Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results finance.yahoo.com - April 29 at 12:50 PM
	Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com - April 29 at 12:50 PM
	Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors finance.yahoo.com - April 28 at 8:20 PM
	Earnings Preview: Morphic Holding, Inc. (MORF) Q1 Earnings Expected to Decline finance.yahoo.com - April 28 at 3:13 PM
	Is Morphic Holding, Inc. (NASDAQ:MORF) Popular Amongst Insiders? finance.yahoo.com - April 27 at 1:48 PM
	Insider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 5,146 Shares of Stock americanbankingnews.com - April 27 at 10:52 AM
	Morphic Holding, Inc. (NASDAQ:MORF) Director Fund V. Gp L.P. Omega Sells 19,787 Shares americanbankingnews.com - April 23 at 7:16 PM
	Insider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 8,081 Shares of Stock americanbankingnews.com - April 21 at 1:26 PM
	Is Morphic Holding a Buy? finance.yahoo.com - April 14 at 9:39 AM
	Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American ... apnews.com - April 12 at 12:46 PM
	Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting finance.yahoo.com - April 12 at 12:46 PM
	THE REVENGE OF SHERLOCK HOLMES! To Embark on UK Spiegel Tent Tour - Broadway World broadwayworld.com - April 2 at 7:44 PM
	Morphic Holding Inc (MORF) CFO and COO Marc Schegerin Bought $190,500 of Shares finance.yahoo.com - March 11 at 7:43 AM
	Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF) nasdaq.com - March 9 at 1:25 PM
	MORF Stock Price: $103 Target (Up From $40) By Wells Fargo pulse2.com - March 7 at 7:21 AM
	Morphic price target raised at Wells Fargo on positive data in inflammatory bowel disease seekingalpha.com - March 3 at 1:22 PM
	Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering finance.yahoo.com - March 3 at 12:38 AM
	Why Morphic Holding Stock Is Falling Today finance.yahoo.com - March 2 at 2:34 PM

Date	Company	Brokerage	Action
4/22/2021	Dicerna Pharmaceuticals	The Goldman Sachs Group	Initiated Coverage
4/19/2021	Dicerna Pharmaceuticals	Truist Securities	Boost Price Target
4/13/2021	Dicerna Pharmaceuticals	SVB Leerink	Lower Price Target
3/8/2021	Dicerna Pharmaceuticals	Chardan Capital	Boost Price Target
3/8/2021	Dicerna Pharmaceuticals	HC Wainwright	Boost Price Target
3/1/2021	Dicerna Pharmaceuticals	B. Riley	Boost Price Target
5/12/2020	Dicerna Pharmaceuticals	Royal Bank of Canada	Initiated Coverage
5/11/2020	Dicerna Pharmaceuticals	SunTrust Banks	Boost Price Target
5/12/2021	Axsome Therapeutics	BTIG Research	Reiterated Rating
3/8/2021	Axsome Therapeutics	Morgan Stanley	Boost Price Target
3/2/2021	Axsome Therapeutics	Mizuho	Lower Price Target
1/8/2021	Axsome Therapeutics	Jefferies Financial Group	Initiated Coverage
12/31/2020	Axsome Therapeutics	UBS Group	Reiterated Rating
12/3/2020	Axsome Therapeutics	Cantor Fitzgerald	Boost Price Target
10/1/2020	Axsome Therapeutics	William Blair	Reiterated Rating
9/29/2020	Axsome Therapeutics	Bank of America	Initiated Coverage
4/28/2020	Axsome Therapeutics	Guggenheim	Boost Price Target
4/27/2020	Axsome Therapeutics	LADENBURG THALM/SH SH	Boost Price Target
4/14/2021	Revance Therapeutics	Needham & Company LLC	Reiterated Rating
10/26/2020	Revance Therapeutics	Barclays	Boost Price Target
4/16/2020	Revance Therapeutics	Stifel Nicolaus	Lower Price Target
2/25/2020	Revance Therapeutics	Piper Sandler	Boost Price Target
3/11/2021	NGM Biopharmaceuticals	Raymond James	Boost Price Target
12/21/2020	NGM Biopharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/21/2020	NGM Biopharmaceuticals	Smith Barney Citigroup	Boost Price Target
6/4/2020	NGM Biopharmaceuticals	BMO Capital Markets	Initiated Coverage
3/23/2020	NGM Biopharmaceuticals	Cowen	Reiterated Rating
3/1/2021	Morphic	Wells Fargo & Company	Boost Price Target

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources